Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3833 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (NET) treated initially with Lanreotide AG and methods of further treatment approaches after progression real-world data

Introduction: .

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślicka A, Bednarczuk T, Osowiecka K, Słoniewska A,

Keywords: advanced NET, non-resectable pancreatic neuroendocrine tumor, Lanreotide therapy, real word data set,

#3588 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (panNETs) treated initially with Octreotide LAR and methods of further treatment after relapse - Real-world data

Introduction: Evaluation of PFS & OS in patients with sporadic, advanced, unresectable, panNET using first line Octreotide therapy need to be further explored.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Bednarczuk T, Osowiecka K, Słoniowska A, Roszkowska K,

Keywords: advance, unresectable pancreatic neuroendocrine tumor, initial octreotide LAR therapy, OS, PFS,

#3142 Patient-reported cognitive and psychological screening in neuroendocrine tumors (NETs): A prospective cohort study

Introduction: An association between neuroendocrine tumors (NET) and neuropsychological symptoms has been suggested, but objective data is limited.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hallet J

Authors: Hallet J, Law C, Kazdan J, Zuk V, Singh S,

Keywords: neuroendocrine, patient-reported, cognitive, depression,

#3141 Incidence of psychiatric illness in patients with neuroendocrine tumors (NET): A comparative population-based analysis

Introduction: Diversion of tryptophan to tumoral hormonal production has been suggested to result in increased prevalence of psychiatric illnesses (PI) in neuroendocrine tumors (NET), but such data are limited to case reports.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hallet J

Authors: Hallet J, Isenberg-Grzeda E, Law C, Zuk V, Sohail S,

Keywords: neuroendocrine, psychiatry, mental health, prognosis,

#2300 Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)

Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Cwikla J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Lanreotide AG systemic therapy,